Defining features of chronic lymphocytic leukemia (CLL) are not only its immunophenotype of CD19+CD5+CD23+sIg dim expressing clonal mature B cells but also its highly variable clinical course. In recent years, advances in massively parallel sequencing technologies have led to rapid progress in our understanding of the CLL genome and epigenome. Overall, these studies have clearly demarcated not only the vast degree of genetic and epigenetic heterogeneity amongst individuals with CLL but also even within individual patient leukemias. We herein review the rapidly growing series of studies assessing the genetic and epigenetic features of CLL within clinically-defined periods of its growth. These studies strongly suggest an evolving spectrum of lesions over time and that these features may have clinical impact.
Introduction
Chronic lymphocytic leukemia (CLL) is an initially slow-growing common B-cell malignancy whose hallmark is a highly variable clinical course. For more than decade, 'watch and wait' has been the standard approach for patients without symptomatic disease, with frontline chemo-based therapy as the conventional choice if treatment is required. Over the past two years, however, three new drugs has been approved: the novel potent CD20-targeting antibody obinutuzumab, 1 the inhibitor of PI3-kinase idelalisib 2 and the irreversible inhibitor of Bruton's tyrosine kinase (BTK) ibrutinib. 3 Moreover, several highly active agents, such as the BCL2 inhibitor GDC-0199/ 4 are in advanced clinical trials, which further promise to expand treatment options.
With these growing therapeutic possibilities, understanding the heterogeneous features of this disease and how it evolves over time becomes a priority so that maximum benefit can be gleaned from these diverse therapies. In parallel with the exciting transformation in the therapeutic landscape of CLL, an explosive growth in our understanding CLL genetics has taken place. 5 Several large-scale studies of massively parallel sequencing have defined the mutation spectrum [6] [7] [8] [9] [10] [11] [12] and have investigated the altered epigenome of CLL. [13] [14] [15] [16] [17] [18] Altogether, these studies have uncovered both the vast genetic and epigenetic heterogeneity amongst patients, and within individual patient samples. Indeed, recent work has demonstrated intratumoral heterogeneity to impact individual evolutionary trajectories and clinical outcome in CLL. 12, 18 These innovations afford the insight that clonal heterogeneity likely fuels clonal evolution and can contribute to the variability in clinical course amongst CLL patients.
Herein, we review recent progress in our understanding of the complexities of inter-and intra-tumoral genetic and epigenetic heterogeneity in relationship to evolutionary principles.
These new data offer fresh perspectives on our approaches to the prognostication and management of CLL.
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The extensive genetic heterogeneity of CLL
Studies of somatic copy number variations using karyotyping, FISH or single nucleotide polymorphism arrays first revealed the high molecular heterogeneity of CLL (extensively reviewed elsewhere). 19, 20 The most recurrent lesions identified were deletions of chromosome 13q (55% of cases), 17p (7%) and 11q (6-18%); and trisomy 12 (12-16%). 21, 22 In addition to their prognostic relevance, the minimal deleted region of each of these deletions have been found to contain within them putative CLL drivers: ATM and BIRC3 in 11q, TP53 in 17p and miR-15a/16 encoded in an intron of DLEU2 in 13q.
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In recent years, the relative affordability of next-generation sequencing (NGS) based technologies such as whole-genome and whole-exome sequencing (WES) has made it feasible to undertake large-scale efforts in cancer sequencing. A primary goal of the initial forays to dissect the CLL genome was to discover, in an unbiased fashion, new drivers based on statistical modeling. Rapid strides in our genetic understanding were gained because of a several salient features of CLL that facilitated genomic investigation, namely, the ready accessibility of purified tumor cells from peripheral blood, its relatively indolent kinetics allowing for repeated sampling over time to study disease evolution; and the highly variable clinical courses of patients which provides a strong distinguishing signal from which the impact of novel features can be differentiates.
Collectively, the earliest NGS-based sequencing studies revealed the overall low somatic mutation rate in CLL (~1/Mb), similar to other hematologic malignancies, but at least 10-fold lower than carcinogen-or UV-induced solid tumors (~15/Mb for melanoma). 24 These studies demonstrated the highly heterogeneous genetic nature of CLL, characterized by several 'mountains' (i.e significantly recurrent genes) but also 'hills' (i.e infrequently recurrent genes), with the lack of any discernible universal genetic event accounting for all cases. [6] [7] [8] [9] [10] [11] These early studies of up to ~100 cases each (with clinically heterogeneous sample cohorts) corroborated known CLL-associated alterations, such as somatic mutations across the length of the DNA damage response genes TP53 and ATM consistent with their inactivating effect.
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Intratumoral genetic heterogeneity provides insights into the order of mutation acquisition in CLL
Despite its clonal origin, cancer is characterized by the coexistence of multiple populations within the tumor. Such intratumoral heterogeneity was conceptualized decades ago as an inevitable outcome of the mutational process inherent to cancers 43, 44 and could be detected using a variety of experimental methods. 45, 46 NGS, however, has been transformative for this effort by providing a comprehensive approach to detect subclones at unprecedented resolution. [47] [48] [49] For CLL, the relative high purity of samples has facilitated the confident detection of rare allelic frequencies of somatic variants, which upon correction for local ploidy and clustering, can lead to the defining of subclonal populations within tumor samples, and hence have led to the understanding of the pervasive extent of intratumoral heterogeneity present in CLL.
The ability to define subclonal architecture in CLL by tumor sequencing has suggested an ability to infer the phylogeny of any case-since the 'snapshot' provided by subclonal composition likely results from the stepwise acquisition of mutations across the process of leukemogenesis (Fig.3A) . For personal use only. on May 29, 2017. by guest www.bloodjournal.org From evolution and the generation of therapy-resistant subpopulations. Through acquisition of fitter subclones and environmental selective pressures, tumors can evolve with time. Indeed, the presence of subclonal driver mutations as a surrogate of an active evolutionary process driving of clonal diversification was found to be an independent poor prognostic risk factor of more aggressive and/or resistant disease. 12, 55 Genetic changes across the disease course of CLL has been investigated in a growing body of studies, which have used longitudinal follow-up of the subclonal composition by various genomic technologies and have illustrated the patterns of clonal evolution across the natural history of CLL (Fig.3B) . 12, 46, [56] [57] [58] [59] Monoclonal B-cell lymphocytosis (MBL) is thought to be the premalignant lesion of CLL.
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Although only a small number of MBL cases have been characterized by WES, a broad heterogeneous spectrum of mutations are clearly present in MBL (including SF3B1, NOTCH1, FBXW7, DDX3X), similar to the mutational spectrum of CLL. 61 In the majority of cases reported thus far, trisomy 12 and del(13q) were also detected by FISH, supporting the idea that these are early lesions in CLL.
Overall, two common patterns of clonal evolution in CLL have been observed. 12, 46, [56] [57] [58] [59] One is that of linear evolution, in which a single clone undergoes successive acquisition of additional driver events over time, that accumulate atop the initial abnormalities. The other is that of branched evolution, in which two or more genetic subclones coexist and evolve in a parallel fashion. In general, inference of subclonal architecture in bulk single timepoint samples using algorithmic approaches cannot necessarily resolve linear vs branched structures of subclonal populations, although recent in silico models have attempted to explore potential evolutionary paths from early to secondary events. 50 Emerging studies evaluating the role of ultra-deep sequencing on the one hand and novel technologies to dissect the mutational profiles of [62] [63] [64] By now, it has become clear that multiple subclones can maintain their relative proportions to each other over years ('clonal equilibrium') while in other cases, individual subclones can emerge as dominant over time likely because of their relative higher fitness ('clonal competition'). The proportion of patients in each of these two categories is likely dependent of stage of disease.
The concepts of clonal equilibrium vs competition and evolution have been most evident in longitudinal studies assessing the impact of cytoreductive therapy. 12, 46, [56] [57] [58] [59] Landau et al.
suggested that the absence of intervening therapy was largely associated with stable subclonal composition over time. In contrast, chemotherapy exposure predominantly resulted in marked clonal evolution. 12 Across studies, the genetic lesions dominating at relapse have been consistently detected in smaller subclones at earlier stages, suggesting the emergence of fitter subclones together with genetic diversification. 50 The most consistent lesion detected in these studies has been preexisting TP53 mutations, resulting in the outgrowth of highly genomically complex clones at relapse. 46 On one hand, genetic lesions such as mutated TP53 itself may confer resistance to the therapeutic agent, and a differential sensitivity of the subclone to these drugs may be responsible for its dominance at relapse. Alternatively, the emergence of a dominant subclone could result from a balanced clonal reduction followed by a competitive release that depends on subclone-related growth properties and mechanisms of tumor progression. Finally, therapy itself could induce de novo mutations conferring major fitness of the related subclones.
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The notion that a coherent pattern of resistance emerging following exposure to therapy has been most clearly demonstrated by recent studies describing resistance developing after exposure to potent inhibition of B-cell receptor signaling with ibrutinib. Resistance was linked to mutations in BTK (C481S) and/or its immediate downstream partner PLCγ2 (Fig.2) . disordered methylation plays a role in CLL initiation, progression and therapeutic resistance.
Potential prognostic impact of the CLL genomic features
Cytogenetic evaluation remains the gold standard and basis for the long-standing hierarchical classification of CLL. 21 However, given that several of novel CLL-associated gene mutations individually have been reported to hold prognostic significance, Rossi et al. previously untreated patients enrolled on the GCLLSG-CLL8 trial, and upon multivariate analysis, found that OS was impacted by TP53 mutation status but not by SF3B1 nor NOTCH1 mutations, while PFS was adversely affected by SF3B1 and TP53 mutations. 31, 82 Patients with NOTCH1 mutations did not benefit from rituximab. By contrast, analyses of the UK-LRF CLL4 trial subjects revealed TP53 disruption, NOTCH1 mutation and SF3B1 mutations as all significantly impacting OS.
33 Two further analyses of clinical trial cohorts (CLL2H-alemtuzumab for fludarabine-refractory patients and CLL3X-reduced-intensity HSCT in poor-risk patients) failed to show any adverse impact of NOTCH1 or SF3B1 mutations on response rate, PFS nor OS after multivariate analysis. 34, 35 Further research studies will be required to definitively establish the role of individual driver mutations on the response to specific therapies.
Incorporating evolutionary concepts into schema for CLL prognosis, monitoring and treatment
The tracking of intratumoral heterogeneity over time can provide critical information on clonal dynamics, which could impact the management of patients. Since the dominant subclones at relapse may be present as minor subclones earlier in disease course, it follows that early detection of these subclones of known high fitness could lead to the contraindication of treatment known to select such clones. One striking example is that of somatic mutations disrupting TP53. Small TP53 mutated subclones identified before treatment appear to anticipate the dominant population at relapse. 83 Presence of mutations leading to TP53 disruption clearly predicts poor response to frontline chemotherapy. Possibly, patients with subclonal TP53 disruption will respond better to novel potent targeted inhibitors (i.e. ibrutinib, idelalisib). [84] [85] [86] In a separate example, recent mathematical modeling of the kinetics of ibrutinib resistance has suggested that such resistant clones are present at the time of
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From the standpoint of therapy, the presence of intratumoral heterogeneity strongly supports on one hand personalized therapies, and on the other hand, the use of therapies that can target multiple vulnerable nodes simultaneously-whether this is through combination therapy, that can include chemotherapy and/or combined targeted inhibition, or even immunotherapy.
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Since clonal equilibrium has been linked to stable disease, a provocative approach for the monitoring and treatment of CLL could be efforts to lead to a more stable state (as observed in early stages patients). The assessment and the monitoring of clonal heterogeneity might be a useful tool to appreciate both the magnitude and the quality of the residual disease. For example, stabilization of the epigenome, which has been recently reported to fuel clonal evolution and diversity in CLL, is now feasible with newly available agents and has not been standardly tested in CLL, and yet may have an impact on limiting the aggressiveness of progressive evolutionary sweeps. Thus, as an "adaptive therapy" strategy, 89 a key goal would be to maintain subclonal relationships such that the emergence of the more resistant clones is prevented. Another potential therapeutic opportunity is presented by the recent data arguing for the occurrence of cancer-driving events at the level of hematopoietic progenitor cells in CLL. Certainly, these findings may explain why, so far, allogeneic hematopoietic 
Concluding remarks
The advent of genome-wide sequencing technologies has uncovered the tremendous genetic and epigenetic heterogeneity of CLL. It remains to be seen the extent to which these features should be taken into account in the management of patients. The identification of novel genetic drivers which has led to the characterization of inter-patient and intratumoral heterogeneity has been shown to clearly impact clinical outcome. Furthermore, a growing series of longitudinal analyses across the stages of CLL disease has delineated not only the heterogeneous trajectories of clonal evolution but also their close link to therapeutic pressure. At the present time, with the ever increasing availability of effective chemotherapy, immunotherapy and agents for the targeted inhibition of key CLL pathways, it is evident that each therapeutic modality provides its own unique mode of selective pressure on a population of CLL cells. Further detailed study in each of these areas using existing or novel (including single cell approaches) genome-wide technologies together with functional analyses in vitro and in vivo will certainly inform us of the relationship between the subclonal architecture in CLL and nodes of therapeutic resistance, and hence provide the critical knowledge gap required for further developing improved individualized and effective therapies for CLL patients. 
C a n c e r C e l l Frequency of gene mutations depending on the course of the disease. 'Early' -newly diagnosed and untreated patients; 'Frontline' -untreated patients with symptomatic CLL requiring therapy; 'R/R' -relapsing or refractory patients. 18 C. Clonal diversification may result from synergic effects of disordered DNA methylation and genomic instability (left); PDR, proportion of discordant reads. Clonal selection related to therapeutic and microenvironment pressure shapes the subclonal composition that ranges from clonal equilibrium to clonal competition (right). High level of clonal diversification could lead to the emergence of fitter subclones competing within CLL bulk and responsible for more aggressive/resistant disease associated with poor survival.
